Also, blocking T cell effector acquisition in vitro during TCR stimulation and expansion with a CD95 blocking antibody or with an AKT1/AKT2 (AKT VIII) inhibitor, has been shown to allow tumor-specific CD8+ T cells to proliferate without differentiating, thereby greatly increasing their numbers and withholding premature apoptosis (24). This evidence concerns the gene AKT1 and neoplasm.